Country: Կանադա
language: անգլերեն
source: Health Canada
RISEDRONATE SODIUM (RISEDRONATE SODIUM HEMIPENTAHYDRATE)
AA PHARMA INC
M05BA07
RISEDRONIC ACID
35MG
TABLET (DELAYED-RELEASE)
RISEDRONATE SODIUM (RISEDRONATE SODIUM HEMIPENTAHYDRATE) 35MG
ORAL
15G/50G
Prescription
BONE RESORPTION INHIBITORS
Active ingredient group (AIG) number: 0135301003; AHFS:
APPROVED
2023-09-08
_Page 1 of 42_ _AA-RISEDRONATE DR (Risedronate Sodium Delayed-Release Tablets)_ PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION PR AA-RISEDRONATE DR Risedronate Sodium Delayed-Release Tablets Delayed-Release Tablets, 35 mg (as the hemi-pentahydrate), Oral Bisphosphonates (ATC Code: M05BA07) Submission Control Number: 278226 AA PHARMA INC. 1165 Creditstone Road, Unit #1 Vaughan, Ontario L4K 4N7 Date of Initial Authorization: SEP 08, 2023 _AA-RISEDRONATE DR (Risedronate Sodium Delayed-Release Tablets) _ _Page 2 of 42 _ RECENT MAJOR LABEL CHANGES Not Applicable TABLE OF CONTENTS SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF AUTHORIZATION ARE NOT LISTED. RECENT MAJOR LABEL CHANGES .......................................................................................... 2 TABLE OF CONTENTS ............................................................................................................ 2 PART I: HEALTH PROFESSIONAL INFORMATION .................................................................... 4 1 INDICATIONS ........................................................................................................ 4 1.1 Pediatrics .............................................................................................................. 4 1.2 Geriatrics .............................................................................................................. 4 2 CONTRAINDICATIONS ........................................................................................... 4 4 DOSAGE AND ADMINISTRATION ........................................................................... 5 4.1 Dosing Considerations ........................................................................................... 5 4.2 Recommended Dose and Dosage Adjustment ......................................................... 5 4.4 Administration....................................................................................................... 5 4.5 Missed Dose ......................................... read_full_document